LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anti-cancer therapy and/or died. LDK378 could be continued beyond RECIST-defined progressive disease (PD) as assessed by the investigator if, in the judgment of the investigator, there was evidence of clinical benefit. In these patients tumor assessment would continue as per the schedule of assessments until treatment with LDK378 was permanently discontinued. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jun 19, 2017 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: LDK378
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Inclusion critieria:
- Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that carries an ALK rearrangement, as per the FDA-approved FISH assay (Abbott Molecular Inc.).
- Age 18 years or older at the time of informed consent.
- Patients must have NSCLC that has progressed during therapy with crizotinib or within 30 days of the last dose
- Patients must have received 1-3 lines of cytotoxic chemotherapy (of which 1 must have been a platinum doublet) to treat their locally advanced or metastatic NSCLC
- Patients must have a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since.
- Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.
- Patients with known hypersensitivity to any of the excipients of LDK378.
- Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
- History of carcinomatous meningitis.
- Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
- Clinically significant, uncontrolled heart disease
- Systemic anti-cancer therapy given after the last dose of crizotinib and prior to starting study drug.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Highlands Oncology Group Dept of Highlands Oncology GrpFayetteville, Arkansas
- City of Hope National Medical Center Dept of Oncology 2Duarte, California
- University of California at Los Angeles Reg-5Los Angeles, California
- University of California at San Diego, Moores Cancer Ctr SCSan Diego, California
- Stanford University Medical Center Stanford Cancer Center(2)Stanford, California
- University of Colorado Hospital SCAurora, Colorado
- Emory University School of Medicine/Winship Cancer Institute Dept of OncologyAtlanta, Georgia
- University of Chicago Medical Center SCChicago, Illinois
- University of Kansas Cancer Center DeptofUofKansas CancerCenter-2Kansas City, Kansas
- Cancer Center of Kansas Dept of CCKWichita, Kansas
- Maryland Oncology Hematology, P.A. SCRockville, Maryland
- Massachusetts General Hospital Mass GeneralBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 19, 2017. Always confirm current availability with the study team.